Literature DB >> 5146410

Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.

J P Morgan, J R Bianchine, H E Spiegel, L Rivera-Calimlim, R M Hersey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5146410     DOI： 10.1001/archneur.1971.00490010049007

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  9 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 2.  Antiparkinsonian drugs: pharmacological and therapeutic aspects.

Authors:  D B Calne; J L Reid
Journal:  Drugs       Date:  1972       Impact factor: 9.546

3.  L-dopa level in plasma, primary condition for the kinetic effect.

Authors:  W Birkmayer; W Danielcyk; E Neumayer; P Riederer
Journal:  J Neural Transm       Date:  1973       Impact factor: 3.575

Review 4.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 5.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

Review 6.  Adverse effects of antiparkinsonian drugs.

Authors:  J D Parkes
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

7.  Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.

Authors:  Frank Schneider; Lavi Erisson; Hooman Beygi; Margaret Bradbury; Orit Cohen-Barak; Igor D Grachev; Serge Guzy; Pippa S Loupe; Micha Levi; Mirna McDonald; Juha-Matti Savola; Spyros Papapetropoulos; William G Tracewell; Maria Velinova; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2018-08-09       Impact factor: 4.335

Review 8.  Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease.

Authors:  Sebastiaan P van Kessel; Sahar El Aidy
Journal:  Front Neurol       Date:  2019-10-15       Impact factor: 4.003

9.  Gut bacterial deamination of residual levodopa medication for Parkinson's disease.

Authors:  Sebastiaan P van Kessel; Hiltje R de Jong; Simon L Winkel; Sander S van Leeuwen; Sieger A Nelemans; Hjalmar Permentier; Ali Keshavarzian; Sahar El Aidy
Journal:  BMC Biol       Date:  2020-10-20       Impact factor: 7.431
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.